NSE: ROSSARI · BSE: 543213
ROSSARI BIOTECH LIMITED
Manufactures specialty chemicals across three core segments — Home Care, Personal Care & Pharma Chemicals (HPPC), Textile Specialty Chemicals (TSC) and Animal Health & Nutrition (AHN) — serving B2B customers in home care, personal care, pharma, textiles, agrochemicals, performance chemicals and animal nutrition. Runs two manufacturing plants at Silvassa and Dahej, with subsidiary Unitop Chemicals providing ethoxylation capacity, and has commissioned a new 5,000 MTPA blending facility in Thailand for Southeast Asian markets. A greenfield project in Saudi Arabia is in progress, with management indicating about 1.5 years from announcement to first kilo of production. Customers in 50+ countries are served, with a dedicated R&D centre in Navi Mumbai supporting an innovation pipeline of biosurfactants, NMMO, MDEA, spray-cooled powders and pharma formulations. The B2C consumer business is being exited while institutional cleaning is retained, with a steady-state 15% EBITDA margin targeted over 2-3 years via product-mix upgrade. Raw materials — primarily ethylene oxide and phenol — are the largest cost at 66.9% of revenue, while the Andheri office was sold and net debt reduced to Rs. 248 crore in Q1 FY27. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Home Care, Personal Care & Pharma Chemicals (HPPC), Textile Specialty Chemicals (TSC), Animal Health & Nutrition (AHN), Institutional cleaning. Cyclical, raw-material-intensive specialty chemicals manufacturer with three segments and ongoing international expansion
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,483 | 1,656 | 1,831 | 2,080 | 2,396 |
| EBITDA (ex other income) | 183 | 223 | 250 | 265 | 286 |
| margin % | 12.4 | 13.5 | 13.6 | 12.7 | 11.9 |
| Owners' profit | 98 | 107 | 131 | 136 | 149 |
| EPS, as reported (₹) | 17.81 | 19.46 | 23.67 | 24.66 | 26.95 |
| ROE % · ROCE % | 12.1 · 15.3 | 11.7 · 16.2 | 12.5 · 17.2 | 11.5 · 14.9 | 11.2 · 15.3 |
| Debt / equity (x) | 0.01 | 0.08 | 0.10 | 0.16 | 0.31 |
| Cash from operations | 29 | 152 | 43 | 137 | 65 |
| Capex | (38) | (33) | (131) | (159) | (265) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 498 | 513 | 580 | 544 | 586 | 582 | 685 | 697 |
| Profit before tax | 48 | 42 | 48 | 46 | 49 | 42 | 64 | 47 |
| Net profit | 35 | 32 | 34 | 34 | 37 | 33 | 46 | 35 |
| EPS (₹) | 6.39 | 5.73 | 6.22 | 6.07 | 6.66 | 5.92 | 8.30 | 6.34 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| PIDILITE INDUSTRIES LTD | 1,42,095 | 53.6 | 12.86 | 37.6 | 22.4 | 28.0 | 14.9 | 28.6 |
| SRF LTD | 69,659 | 32.2 | 4.96 | 21.6 | 13.1 | 13.1 | 13.4 | 25.2 |
| GUJARAT FLUOROCHEM LTD | 47,075 | 76.8 | 5.95 | 37.4 | 7.3 | 8.7 | 13.5 | 27.7 |
| NAVIN FLUORINE INT. LTD | 43,610 | 55.1 | 10.97 | 39.3 | 16.7 | 16.4 | 23.0 | 37.5 |
| AETHER INDUSTRIES LIMITED | 20,905 | 88.6 | 8.51 | 56.8 | 8.9 | 11.4 | — | 33.8 |
| DEEPAK NITRITE LTD | 20,257 | 25.9 | 3.45 | 21.0 | 9.4 | 10.2 | 12.6 | 21.5 |
| AARTI INDUSTRIES LTD | 15,871 | 29.9 | 2.67 | 17.1 | 7.0 | 4.4 | 13.0 | 16.2 |
| FINE ORGANIC IND. LTD. | 15,604 | 35.6 | 5.86 | 25.5 | 15.7 | 20.0 | 15.9 | 28.8 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 15.1 | 23.1 | 28 of 99 | 72% |
| P/B | 1.7 | 2.8 | 32 of 99 | 67% |
| ROCE | 13.4 | 10.1 | 39 of 106 | 64% |
| ROE | 11.2 | 8.1 | 39 of 99 | 61% |
| Debt / Equity | 0.3 | 0.2 | 65 of 99 | 35% |
| EBITDA margin | 12.0 | 15.5 | 66 of 99 | 34% |
| Revenue growth | 28.2 | 24.4 | 37 of 94 | 61% |
| Profit growth | 4.5 | 55.1 | 71 of 92 | 23% |
| Market cap | 2275 | 699 | 35 of 108 | 68% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 22 Oct 2026 · Q2 FY27 revenue hits record Rs 697.6 crore; margin improvement planned | investor communications | medium | — | — |
| 19 Oct 2026 · Audio recording of Q2 and H1 FY27 earnings call available on website | investor communications | medium | — | — |
| 19 Oct 2026 · Rossari Biotech Q2 FY27: Record revenue Rs 698 cr, up 19% YoY | compliance | low | — | — |
| 19 Oct 2026 · Rossari Biotech Q2 FY27: record revenue Rs 697 cr, EBITDA up 21% | investor communications | medium | — | — |
| 18 Oct 2026 · Rossari Biotech Q2 FY27 results: revenue up 19%, profit up 5.5% YoY | compliance | minimal | — | — |
| 17 Oct 2026 · Rossari Biotech Q2 revenue up 19% YoY, H1 revenue up 23%, PAT up 5% | results | high | — | — |
| 17 Oct 2026 · Q2 FY27 Results: Revenue up 19% YoY, PAT up 5%; Saudi plant approved | results | high | — | — |
| 17 Oct 2026 · Q2 FY26 Results: Revenue up 19% YoY; KSA plant approved | board shareholder meetings | low | — | — |
| 14 Oct 2026 · Rossari Biotech Q2 and H1 FY27 earnings call on October 19 at 4 PM | board shareholder meetings | low | — | — |
| 9 Oct 2026 · Board meeting on Oct 17, 2026 to approve Q2 FY27 results | results | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.